Dual receptor antagonistic antigen-binding proteins and uses thereof
This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
1. An isolated antigen-binding protein comprising a first polypeptide comprising SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and a second polypeptide comprising SEQ ID NO:6, SEQ ID NO: 7 and SEQ ID NO:8 wherein the isolated antigen-binding protein specifically binds to SEQ ID NO: 2 and SEQ ID NO: 18.
2. The isolated antigen binding protein of claim 1 , the first polypeptide comprising SEQ ID NO: 15 and the second polypeptide comprising SEQ ID NO: 16.
3. The isolated antigen binding protein of claim 1 , the first polypeptide having at least 97% sequence identity to SEQ ID NO:15 and the second polypeptide having at least 97% sequence identity to SEQ ID NO:16.
4. The antigen-binding protein of claim 1 comprising at least one characteristic selected from the group consisting of: upon binding to SEQ ID NO:2 and SEQ ID NO:18, stimulates muscle growth; has a K D for ActRIIB of 10 pM or less in a BIAcore assay; has a K D for ActRIIB of 1 pM or less in a BIAcore assay; has a K D for ActRIIA of 4 nM or less in a BIAcore assay; has a K D for ActRIIA of 1 pM or less in a BIAcore assay; has a K D for ActRIIB and ActRIIA of 1 pM or less in a BIAcore assay; has an IC 50 for ActRIIB of 8 nm or less in a cell-based assay; has an IC 50 for ActRIIB of 2 nM or less in a cell-based assay; has an IC 50 for ActRIIA of 2 nM or less in a cell-based assay; has an IC 50 for ActRIIA of 1 nM or less in a cell-based assay; or has a IC 50 for ActRIIB of 2 nM or less and a IC 50 ActRIIA of 1 nM or less in a cell-based assay.
5. The antigen-binding protein of claim 1 , wherein said antigen-binding protein is a monoclonal antibody or fragment thereof.
6. The antigen-binding protein of claim 1 , wherein said antigen-binding protein is a humanized antibody, a human antibody, a chimeric antibody, a multispecific antibody, or fragment of a humanized antibody, a human antibody, a chimeric antibody or a multispecific antibody or an antagonistic dual receptor antibody.
7. An isolated nucleic acid encoding an antigen-binding protein comprising a first polypeptide comprising SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and a second polypeptide comprising SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8 wherein the antigen-binding protein specifically binds to SEQ ID NO: 2 and SEQ ID NO: 18.
8. An expression vector comprising the nucleic acid of claim 7 .
9. A host cell comprising the vector of claim 8 .
10. The host cell of claim 9 wherein the cell is a eukaryotic cell.
11. The host cell of claim 10 wherein the eukaryotic cell is a mammalian cell.
12. A method of producing an antigen-binding protein, comprising culturing the host cell of claim 9 under suitable conditions such that the nucleic acid is expressed to produce the antigen binding protein.
13. The method of claim 12 , further comprising recovering the antigen binding protein from a culture of the host cell.
14. A composition comprising the antigen-binding protein of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
15. A method of reducing or blocking myostatin, activin A or GDF-11 activity comprising administering a therapeutically effective amount of the antigen-binding protein of claim 1 to a subject in need of such treatment.
16. A method of increasing lean muscle mass or increasing the ratio of lean muscle mass to fat mass in a subject in need of such treatment comprising administering an effective amount the antigen-binding protein of claim 1 to a subject in need of such treatment.
17. The method of claim 16 , wherein the subject is a mouse.
18. A composition comprising the antigen-binding protein of claim 2 and a pharmaceutically acceptable carrier, diluent or excipient.
19. A method of reducing or blocking myostatin, activin A or GDF-11 activity comprising administering a therapeutically effective amount of the antigen-binding protein of claim 2 to a subject in need of such treatment.
20. A method of increasing lean muscle mass or increasing the ratio of lean muscle mass to fat mass in a subject in need of such treatment comprising administering an effective amount the antigen-binding protein of claim 2 to a subject in need of such treatment.
21. The method of claim 20 , wherein the subject is a mouse.